AlphAIAlphAI — Financial news for AI agents
prnewswire.comSEP 252 min read$RGNX

REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting

REGENXBIO (Nasdaq: RGNX) presented positive three-year data from its Phase II ALTITUDE study of surabgene lomparvovec for diabetic retinopathy at the Retina Society Annual Meeting. The data showed durable efficacy with 60% of participants achieving a >2-step improvement on the DRSS. No new safety signals were observed. The company is advancing the treatment in a Phase IIb/III trial.

Original reporting
prnewswire.com
Published Sep 25, 2026, 12:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 25, 2026, 1:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting — source image
Source · prnewswire.com
Decision brief

The 30-second read

$RGNXBullishMed
01

Why it matters

The data suggest a potentially transformative one‑time treatment, which could drive investor optimism and affect RGNX valuation.

02

Market read

First disclosure of durable Phase II data for a retinal gene therapy; likely to influence biotech sentiment and RGNX stock movement.

03

What to watch

Regulatory timeline and potential competition from other retinal therapies could temper upside.

Relevance 8/10Novelty 9/10Timing: presented today at the Retina Society Annual Scientific Meeting

Background

Regenxbio (Nasdaq: RGNX) announced three‑year follow‑up results from its Phase II ALTITUDE study of surabgene lomparvovec (sura‑vec) for non‑proliferative diabetic retinopathy, showing sustained efficacy and no new safety signals.

Company-level read

Ticker impact

$RGNXBullishMedium confidence
Context

Regenxbio presented positive three-year durability data for surabgene lomparvovec in diabetic retinopathy at the Retina Society meeting.

Expected impact

Potential upside as investors price in a differentiated gene‑therapy platform; short‑term rally possible.

Evidence & confidence

First disclosure of long‑term data for a late‑stage retinal gene therapy; market typically reacts positively to durable efficacy signals.

Market effects

Sector

Strengthens the gene‑therapy and ophthalmology sectors, may boost peer biotech valuations.

Regional

U.S. biotech investors likely to respond; limited immediate impact on broader markets.

Global

Highlights progress in gene‑therapy platforms, relevant to global investors tracking biotech innovation.

Counterpoint

What could challenge this read

Data set is small (n=10) and long‑term durability still unproven; investors may remain cautious.

Key entities

  • company
    Regenxbio Inc.

    Biotech company developing AAV gene‑therapy platforms.

  • partner
    AbbVie

    Collaborates with Regenxbio on surabgene lomparvovec.

Read at source← All news

Related articles

SEP 25
$RGNXMedAI 8/10

Why is Regenxbio stock climbing today?

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

investing.com2 min
SEP 25
$AKAMMed

Nasdaq, S&P 500 Futures Rise Despite Surging Treasury Yields: AMD, TSLA, SPCX, AKAM, BE Stocks In Focus

Nasdaq and S&P 500 futures rose despite surging Treasury yields. Akamai (AKAM) surged 20% after a $11.6B deal with Anthropic. Tesla (TSLA) trended upward following a next-gen Roadster unveil and Semi truck production news. SpaceX (SPCX) gained on AI model predictions. Bloom Energy (BE) rose 1% after reaffirming Oracle's (ORCL) fuel-cell contract. Comcast (CMCSA) fell on analyst downgrades. Regenxbio (RGNX) rose 2% on positive gene therapy data.

finance.yahoo.com3 min
SEP 23
$RGNXMedAI 8/10

FDA Should Demand Proof, Not Just Protein, for Duchenne

The FDA is scrutinizing REGENXBIO's RGX-202 and Solid Biosciences' SGT-003, both Duchenne muscular dystrophy treatments, for accelerated approval. The FDA requires evidence that microdystrophin expression predicts clinical benefit, citing Pfizer's failed CIFFREO trial as a cautionary example. REGENXBIO reported 93% of patients reached 10% microdystrophin expression, but functional data is limited. The FDA seeks robust evidence before approval, given the permanent nature of gene therapy.

pjmedia.com3 min
SEP 17
$XMTRMedAI 8/10

Six Montgomery County companies attract more than $566 million in capital investment – WTOP News

Six Montgomery County companies raised over $566 million in Q3. Forbright (Nasdaq) completed an IPO, raising $142.2 million. Xometry (Nasdaq) announced a $225 million secondary offering. RegenxBio (Nasdaq) raised $90.04 million in a public offering. Georgiamune secured $92.69 million in venture funding. Arculus Solutions raised $1.95 million in Seed-1 funding. Jesse & Ben raised $15 million in Series A funding.

wtop.com3 min
SEP 5
$RGNXHighAI 8/10

Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome

Regenxbio Inc. (RGNX) faced an FDA clinical hold for RGX-121, its gene therapy for Hunter syndrome, due to spinal abnormalities in five patients. Shares fell over 24% premarket. The abnormalities were deemed non-serious and likely benign, with patients asymptomatic. The FDA's full clinical-hold letter and additional data are awaited to determine next steps.

insidermonkey.com2 min